Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Extending Visit Intervals for Clinically Stable Patients on Antiretroviral Therapy: Multicohort Analysis of HIV Programs in Southern Africa.

Haas AD, Johnson LF, Grimsrud A, Ford N, Mugglin C, Fox MP, Euvrard J, van Lettow M, Prozesky H, Sikazwe I, Chimbetete C, Hobbins M, Kunzekwenyika C, Egger M; for IeDEA Southern Africa.

J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):439-447. doi: 10.1097/QAI.0000000000002060.

PMID:
31242142
2.

Medication Side Effects and Retention in HIV Treatment: A Regression Discontinuity Study of Tenofovir Implementation in South Africa and Zambia.

Brennan AT, Bor J, Davies MA, Wandeler G, Prozesky H, Fatti G, Wood R, Stinson K, Tanser F, Bärnighausen T, Boulle A, Sikazwe I, Zanolini A, Fox MP.

Am J Epidemiol. 2018 Sep 1;187(9):1990-2001. doi: 10.1093/aje/kwy093.

3.

Seasonal variations in tuberculosis diagnosis among HIV-positive individuals in Southern Africa: analysis of cohort studies at antiretroviral treatment programmes.

Ballif M, Zürcher K, Reid SE, Boulle A, Fox MP, Prozesky HW, Chimbetete C, Zwahlen M, Egger M, Fenner L; International Epidemiology Database to Evaluate AIDS in Southern Africa (IeDEA-SA).

BMJ Open. 2018 Jan 11;8(1):e017405. doi: 10.1136/bmjopen-2017-017405.

4.

Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes.

Rohr JK, Ive P, Horsburgh CR, Berhanu R, Hoffmann CJ, Wood R, Boulle A, Giddy J, Prozesky H, Vinikoor M, Mwanza MW, Wandeler G, Davies MA, Fox MP.

J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):413-416. doi: 10.1097/QAI.0000000000001611.

5.

AIDS-Related Endemic Mycoses in Western Cape, South Africa, and Clinical Mimics: A Cross-Sectional Study of Adults With Advanced HIV and Recent-Onset, Widespread Skin Lesions.

Schwartz IS, Kenyon C, Lehloenya R, Claasens S, Spengane Z, Prozesky H, Burton R, Parker A, Wasserman S, Meintjes G, Mendelson M, Taljaard J, Schneider JW, Beylis N, Maloba B, Govender NP, Colebunders R, Dlamini S.

Open Forum Infect Dis. 2017 Aug 25;4(4):ofx186. doi: 10.1093/ofid/ofx186. eCollection 2017 Fall.

6.

Twelve-year mortality in adults initiating antiretroviral therapy in South Africa.

Cornell M, Johnson LF, Wood R, Tanser F, Fox MP, Prozesky H, Schomaker M, Egger M, Davies MA, Boulle A; International Epidemiology Databases to Evaluate AIDS-Southern Africa collaboration.

J Int AIDS Soc. 2017 Sep 25;20(1):21902. doi: 10.7448/IAS.20.1.21902.

7.

HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration.

Jiamsakul A, Kariminia A, Althoff KN, Cesar C, Cortes CP, Davies MA, Do VC, Eley B, Gill J, Kumarasamy N, Machado DM, Moore R, Prozesky H, Zaniewski E, Law M.

J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):319-329. doi: 10.1097/QAI.0000000000001499.

8.

HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies.

Fenner L, Atkinson A, Boulle A, Fox MP, Prozesky H, Zürcher K, Ballif M, Furrer H, Zwahlen M, Davies MA, Egger M; International Epidemiology Database to Evaluate AIDS in Southern Africa (IeDEA-SA).

J Int AIDS Soc. 2017 Jun 23;20(1):21327. doi: 10.7448/IAS.20.1.21327.

9.

Where do HIV-infected adolescents go after transfer? - Tracking transition/transfer of HIV-infected adolescents using linkage of cohort data to a health information system platform.

Davies MA, Tsondai P, Tiffin N, Eley B, Rabie H, Euvrard J, Orrell C, Prozesky H, Wood R, Cogill D, Haas AD, Sohn AH, Boulle A.

J Int AIDS Soc. 2017 May 16;20(Suppl 3):21668. doi: 10.7448/IAS.20.4.21668.

10.

Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?

Brennan AT, Davies MA, Bor J, Wandeler G, Stinson K, Wood R, Prozesky H, Tanser F, Fatti G, Boulle A, Sikazwe I, Wool-Kaloustian K, Yuannoutsos C, Leroy V, de Rekeneire N, Fox MP.

AIDS. 2017 Jan 2;31(1):147-157.

11.

Life expectancy trends in adults on antiretroviral treatment in South Africa.

Johnson LF, Keiser O, Fox MP, Tanser F, Cornell M, Hoffmann CJ, Prozesky H, Boulle A, Davies MA; International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration.

AIDS. 2016 Oct 23;30(16):2545-2550.

12.

Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia.

Pediatric AIDS-Defining Cancer Project Working Group for IeDEA Southern Africa, TApHOD, and COHERE in EuroCoord, Rohner E, Schmidlin K, Zwahlen M, Chakraborty R, Clifford G, Obel N, Grabar S, Verbon A, Noguera-Julian A, Collins IJ, Rojo P, Brockmeyer N, Campbell M, Chêne G, Prozesky H, Eley B, Stefan DC, Davidson A, Chimbetete C, Sawry S, Davies MA, Kariminia A, Vibol U, Sohn A, Egger M, Bohlius J.

Clin Infect Dis. 2016 Nov 1;63(9):1245-1253. Epub 2016 Aug 30.

13.

Incidence of AIDS-defining and Other Cancers in HIV-positive Children in South Africa: Record Linkage Study.

Bohlius J, Maxwell N, Spoerri A, Wainwright R, Sawry S, Poole J, Eley B, Prozesky H, Rabie H, Garone D, Technau KG, Maskew M, Davies MA, Davidson A, Stefan DC, Egger M; for IeDEA-Southern Africa.

Pediatr Infect Dis J. 2016 Jun;35(6):e164-70. doi: 10.1097/INF.0000000000001117.

14.

CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study.

Grimsrud A, Cornell M, Schomaker M, Fox MP, Orrell C, Prozesky H, Stinson K, Tanser F, Egger M, Myer L; International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration (IeDEA-SA).

J Epidemiol Community Health. 2016 Jun;70(6):549-55. doi: 10.1136/jech-2015-206629. Epub 2015 Dec 23.

15.

A comparison of death recording by health centres and civil registration in South Africans receiving antiretroviral treatment.

Johnson LF, Dorrington RE, Laubscher R, Hoffmann CJ, Wood R, Fox MP, Cornell M, Schomaker M, Prozesky H, Tanser F, Davies MA, Boulle A; International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration.

J Int AIDS Soc. 2015 Dec 16;18:20628. doi: 10.7448/IAS.18.1.20628. eCollection 2015.

16.

Implementation and Operational Research: Risk Charts to Guide Targeted HIV-1 Viral Load Monitoring of ART: Development and Validation in Patients From Resource-Limited Settings.

Koller M, Fatti G, Chi BH, Keiser O, Hoffmann CJ, Wood R, Prozesky H, Stinson K, Giddy J, Mutevedzi P, Fox MP, Law M, Boulle A, Egger M.

J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):e110-9. doi: 10.1097/QAI.0000000000000748.

17.

Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study.

Cornell M, Johnson LF, Schomaker M, Tanser F, Maskew M, Wood R, Prozesky H, Giddy J, Stinson K, Egger M, Boulle A, Myer L; International Epidemiologic Databases to Evaluate AIDS-Southern Africa Collaboration.

Lancet HIV. 2015 Sep;2(9):e368-75. doi: 10.1016/S2352-3018(15)00113-7. Epub 2015 Aug 4.

18.

Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings.

Huisin ʼt Veld D, Balestre E, Buyze J, Menten J, Jaquet A, Cooper DA, Dabis F, Yiannoutsos CT, Diero L, Mutevedzi P, Fox MP, Messou E, Hoffmann CJ, Prozesky HW, Egger M, Hemingway-Foday JJ, Colebunders R; International Epidemiologic Databases to Evaluate AIDS (IeDEA).

J Acquir Immune Defic Syndr. 2015 Oct 1;70(2):146-54. doi: 10.1097/QAI.0000000000000691.

19.

Clinical Characteristics, Diagnosis, Management, and Outcomes of Disseminated Emmonsiosis: A Retrospective Case Series.

Schwartz IS, Govender NP, Corcoran C, Dlamini S, Prozesky H, Burton R, Mendelson M, Taljaard J, Lehloenya R, Calligaro G, Colebunders R, Kenyon C.

Clin Infect Dis. 2015 Sep 15;61(6):1004-12. doi: 10.1093/cid/civ439. Epub 2015 Jun 9.

PMID:
26060283
20.

CD41 T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa.

Geng EH, Neilands TB, Thièbaut R, Bwana MB, Nash D, Moore RD, Wood R, Zannou DM, Althoff KN, Lim PL, Nachega JB, Easterbrook PJ, Kambugu A, Little F, Nakigozi G, Nakanjako D, Kiggundu V, Ki Li PC, Bangsberg DR, Fox MP, Prozesky H, Hunt PW, Davies MA, Reynolds SJ, Egger M, Yiannoutsos CT, Vittinghoff EV, Deeks SG, Martin JN.

Int J Epidemiol. 2015 Feb;44(1):251-63.

21.

Incidence rate of Kaposi sarcoma in HIV-infected patients on antiretroviral therapy in Southern Africa: a prospective multicohort study.

Rohner E, Valeri F, Maskew M, Prozesky H, Rabie H, Garone D, Dickinson D, Chimbetete C, Lumano-Mulenga P, Sikazwe I, Wyss N, Clough-Gorr KM, Egger M, Chi BH, Bohlius J.

J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):547-54. doi: 10.1097/QAI.0000000000000360.

22.

Kaposi's Sarcoma in HIV-infected patients in South Africa: Multicohort study in the antiretroviral therapy era.

Bohlius J, Valeri F, Maskew M, Prozesky H, Garone D, Sengayi M, Fox MP, Davies MA, Egger M.

Int J Cancer. 2014 Dec 1;135(11):2644-52. doi: 10.1002/ijc.28894. Epub 2014 May 2.

23.

Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries.

IeDEA and ART Cohort Collaborations, Avila D, Althoff KN, Mugglin C, Wools-Kaloustian K, Koller M, Dabis F, Nash D, Gsponer T, Sungkanuparph S, McGowan C, May M, Cooper D, Chimbetete C, Wolff M, Collier A, McManus H, Davies MA, Costagliola D, Crabtree-Ramirez B, Chaiwarith R, Cescon A, Cornell M, Diero L, Phanuphak P, Sawadogo A, Ehmer J, Eholie SP, Li PC, Fox MP, Gandhi NR, González E, Lee CK, Hoffmann CJ, Kambugu A, Keiser O, Ditangco R, Prozesky H, Lampe F, Kumarasamy N, Kitahata M, Lugina E, Lyamuya R, Vonthanak S, Fink V, d'Arminio Monforte A, Luz PM, Chen YM, Minga A, Casabona J, Mwango A, Choi JY, Newell ML, Bukusi EA, Ngonyani K, Merati TP, Otieno J, Bosco MB, Phiri S, Ng OT, Anastos K, Rockstroh J, Santos I, Oka S, Somi G, Stephan C, Teira R, Wabwire D, Wandeler G, Boulle A, Reiss P, Wood R, Chi BH, Williams C, Sterne JA, Egger M.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):e8-16. doi: 10.1097/QAI.0b013e3182a39979.

24.

Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.

Wandeler G, Gerber F, Rohr J, Chi BH, Orrell C, Chimbetete C, Prozesky H, Boulle A, Hoffmann CJ, Gsponer T, Fox MP, Zwahlen M, Egger M; IeDEA Southern Africa.

Antivir Ther. 2014;19(5):521-5. doi: 10.3851/IMP2710. Epub 2013 Dec 3.

25.

A dimorphic fungus causing disseminated infection in South Africa.

Kenyon C, Bonorchis K, Corcoran C, Meintjes G, Locketz M, Lehloenya R, Vismer HF, Naicker P, Prozesky H, van Wyk M, Bamford C, du Plooy M, Imrie G, Dlamini S, Borman AM, Colebunders R, Yansouni CP, Mendelson M, Govender NP.

N Engl J Med. 2013 Oct 10;369(15):1416-24. doi: 10.1056/NEJMoa1215460.

26.

Zidovudine impairs immunological recovery on first-line antiretroviral therapy: collaborative analysis of cohort studies in southern Africa.

Wandeler G, Gsponer T, Mulenga L, Garone D, Wood R, Maskew M, Prozesky H, Hoffmann C, Ehmer J, Dickinson D, Davies MA, Egger M, Keiser O; IeDEA Southern Africa Collaboration.

AIDS. 2013 Sep 10;27(14):2225-32. doi: 10.1097/QAD.0b013e328362d887.

27.

Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies.

Johnson LF, Mossong J, Dorrington RE, Schomaker M, Hoffmann CJ, Keiser O, Fox MP, Wood R, Prozesky H, Giddy J, Garone DB, Cornell M, Egger M, Boulle A; International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration.

PLoS Med. 2013;10(4):e1001418. doi: 10.1371/journal.pmed.1001418. Epub 2013 Apr 9.

28.

Immune recovery after starting ART in HIV-infected patients presenting and not presenting with tuberculosis in South Africa.

Schomaker M, Egger M, Maskew M, Garone D, Prozesky H, Hoffmann CJ, Boulle A, Fenner L; IeDEA Southern Africa.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):142-5. doi: 10.1097/QAI.0b013e318288b39d.

29.

CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa.

Hoffmann CJ, Schomaker M, Fox MP, Mutevedzi P, Giddy J, Prozesky H, Wood R, Garone DB, Egger M, Boulle A; IeDEA Southern Africa Collaboration.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):34-41. doi: 10.1097/QAI.0b013e318287c1fe.

30.

Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa.

Fenner L, Reid SE, Fox MP, Garone D, Wellington M, Prozesky H, Zwahlen M, Schomaker M, Wandeler G, Kancheya N, Boulle A, Wood R, Henostroza G, Egger M; IeDEA Southern Africa.

Trop Med Int Health. 2013 Feb;18(2):194-8. doi: 10.1111/tmi.12026. Epub 2012 Nov 30.

31.

Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.

Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, Maskew M, Prozesky H, Wood R, Johnson LF, Egger M, Boulle A, Myer L; International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration.

PLoS Med. 2012;9(9):e1001304. Epub 2012 Sep 4.

32.

Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.

Wandeler G, Keiser O, Mulenga L, Hoffmann CJ, Wood R, Chaweza T, Brennan A, Prozesky H, Garone D, Giddy J, Chimbetete C, Boulle A, Egger M; IeDEA Southern Africa Collaboration.

J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):41-8.

33.

Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa.

Fox MP, Cutsem GV, Giddy J, Maskew M, Keiser O, Prozesky H, Wood R, Hernán MA, Sterne JA, Egger M, Boulle A; IeDEA-SA collaboration.

J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):428-37. doi: 10.1097/QAI.0b013e3182557785.

34.

Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa.

Keiser O, Chi BH, Gsponer T, Boulle A, Orrell C, Phiri S, Maxwell N, Maskew M, Prozesky H, Fox MP, Westfall A, Egger M; IeDEA Southern Africa Collaboration.

AIDS. 2011 Sep 10;25(14):1761-9. doi: 10.1097/QAD.0b013e328349822f.

35.

Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007.

Cornell M, Grimsrud A, Fairall L, Fox MP, van Cutsem G, Giddy J, Wood R, Prozesky H, Mohapi L, Graber C, Egger M, Boulle A, Myer L; International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration.

AIDS. 2010 Sep 10;24(14):2263-70. doi: 10.1097/QAD.0b013e32833d45c5.

36.

Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa.

Fenner L, Brinkhof MW, Keiser O, Weigel R, Cornell M, Moultrie H, Prozesky H, Technau K, Eley B, Vaz P, Pascoe M, Giddy J, Van Cutsem G, Wood R, Egger M, Davies MA; International epidemiologic Databases to Evaluate AIDS in Southern Africa.

J Acquir Immune Defic Syndr. 2010 Aug;54(5):524-32. doi: 10.1097/QAI.0b013e3181e0c4cf.

37.

Prioritising prevention strategies for patients in antiretroviral treatment programmes in resource-limited settings.

Spaar A, Graber C, Dabis F, Coutsoudis A, Bachmann L, McIntyre J, Schechter M, Prozesky HW, Tuboi S, Dickinson D, Kumarasamy N, Pujdades-Rodriquez M, Sprinz E, Schilthuis HJ, Cahn P, Low N, Egger M; ART-LINC of IeDEA.

AIDS Care. 2010 Jun;22(6):775-83. doi: 10.1080/09540120903349102.

38.

Evaluation of paradoxical TB-associated IRIS with the use of standardized case definitions for resource-limited settings.

Eshun-Wilson I, Havers F, Nachega JB, Prozesky HW, Taljaard JJ, Zeier MD, Cotton M, Simon G, Soentjens P.

J Int Assoc Physicians AIDS Care (Chic). 2010 Mar-Apr;9(2):104-8. doi: 10.1177/1545109710361537. Epub 2010 Feb 16.

39.

Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the IeDEA Southern Africa collaboration.

Cornell M, Technau K, Fairall L, Wood R, Moultrie H, van Cutsem G, Giddy J, Mohapi L, Eley B, MacPhail P, Prozesky H, Rabie H, Davies MA, Maxwell N, Boulle A; International epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration.

S Afr Med J. 2009 Sep;99(9):653-60.

40.

Protease inhibitor resistance in South African children with virologic failure.

van Zyl GU, van der Merwe L, Claassen M, Cotton MF, Rabie H, Prozesky HW, Preiser W.

Pediatr Infect Dis J. 2009 Dec;28(12):1125-7. doi: 10.1097/INF.0b013e3181af829d.

PMID:
19779394
41.

Combined antiretroviral treatment initiation during hospitalization: outcomes in South African adults.

Eshun-Wilson I, Plas HV, Prozesky HW, Zeier MD, Nachega J, Taljaard JJ.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):105-6. doi: 10.1097/QAI.0b013e3181963cd4. No abstract available.

42.
43.

Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review.

Muula AS, Ngulube TJ, Siziya S, Makupe CM, Umar E, Prozesky HW, Wiysonge CS, Mataya RH.

BMC Public Health. 2007 Apr 25;7:63. Review.

44.

Prevalence of complications of male circumcision in Anglophone Africa: a systematic review.

Muula AS, Prozesky HW, Mataya RH, Ikechebelu JI.

BMC Urol. 2007 Mar 2;7:4. Review.

Supplemental Content

Loading ...
Support Center